Orphan Disease Focus GeNeuro targets neurodegenerative and inflammatory conditions linked to HERVs, including MS, ALS, and long COVID. Sales opportunities exist with specialty pharma and CROs serving neurodegenerative disease programs, as well as fundraising for rare disease initiatives and academic collaborations.

Clinical Pipeline maturity Active Phase 2 trial for temelimab (GNC-501) and preclinical programs like GN-K01 indicate ongoing development and potential near-to-mid-term inflection points. Business development can prioritize strategic partnerships or co-development rights around near-term readouts and milestone-driven deals.

Strategic Financing Recent €5M+ financing and EIB-backed credit facility signal investor confidence and liquidity for clinical progression. This enables partnership discussions around funding-for-completion milestones, translational studies, or joint ventures to accelerate value realization.

Global Collaboration Existing collaboration with European institutions (EIB, NINDS preclinical programs) suggests openness to international research alliances. Opportunities exist to propose multinational trials, grant-funded programs, and licensing opportunities to extend geographic reach.

Evidence-driven Value Alternatively targeting long COVID and cognitive impairment endpoints offers a differentiator in the neurology space. Sell the value of anti-HERV therapies as a novel mechanism with potential disease-modifying effects to biotech partners seeking innovative assets with first-in-class potential.